Baillie Gifford & Co’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Baillie Gifford & Co’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-892	Closed	-$61K	–	497
2022 Q3	$61K	Buy	892 +57	+7%	+$3.14K	﹤0.01%	296
2022 Q2	$27K	Hold	835	–	–	﹤0.01%	316
2022 Q1	$29K	Hold	835	–	–	﹤0.01%	322
2021 Q4	$24K	Hold	835	–	–	﹤0.01%	357
2021 Q3	$21K	Sell	835 -119	-12%	-$3.5K	﹤0.01%	372
2021 Q2	$33K	Sell	954 -53	-5%	-$2.07K	﹤0.01%	310
2021 Q1	$41K	Buy	1,007 +57	+6%	+$2.62K	﹤0.01%	290
2020 Q4	$41K	Buy	+950	New	+$46.8K	﹤0.01%	278

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Baillie Gifford & Co's GBT Position: Q4 2022 in Review

Baillie Gifford & Co sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 892 shares — an estimated $61K sold.

Baillie Gifford & Co first reported a position in GBT in Q4 2020 and held it in 8 quarters. The position peaked at $61K in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Baillie Gifford & Co reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Baillie Gifford & Co sold 892 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $61K.
Baillie Gifford & Co first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 8 quarters.
Baillie Gifford & Co's Global Blood Therapeutics, Inc. position peaked at $61K in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Baillie Gifford & Co's 13F filing for Q4 2022, filed 24 Jan 2023.